Healthcare / Drug Manufacturers - Specialty & GenericMCE
$2.70
-0.01 (-0.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $6.3M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$220M
P/E
54.0x
↑EV/EBITDA
9.3x
↓ROE
2.3%
↑Gross Margin
59.2%
↑Debt/Equity
0.42
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.9%
FCF CAGR
—
FCF margin
-5.1%
FCF / Net income
-3.34x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $331.1M · net income $5.0M · FCF $-16.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $331.1M | $331.1M | $338.9M | $316.1M | $271.1M |
| Net Income | $5.0M | $5.0M | $10.4M | $9.4M | $8.1M |
| EBITDA | $32.5M | $32.5M | $36.2M | $34.4M | $30.5M |
| EPS | 0.06 | 0.06 | 0.13 | 0.12 | 0.10 |
| Gross Margin | 59.2% | 59.2% | 57.7% | 56.6% | 58.0% |
| Operating Margin | 2.1% | 2.1% | 4.4% | 3.9% | 3.4% |
| Net Margin | 1.5% | 1.5% | 3.1% | 3.0% | 3.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.42 | 0.42 | 0.27 | 0.26 | 0.31 |
| Current Ratio | 1.55 | 1.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-16.8M | $-16.8M | $10.6M | $6.3M | $4.7M |
| Returns | |||||
| ROE | 2.3% | 2.3% | 4.9% | 4.6% | 4.2% |
| Valuation | |||||
| P/E | 54.00 | 54.00 | 19.66 | 19.42 | 23.00 |
| EV/EBITDA | 9.26 | 9.26 | 7.01 | 6.82 | 7.74 |
| P/B | 1.01 | 1.01 | 0.96 | 0.91 | 0.93 |
| Growth & Yield | |||||
| Revenue Growth | -2.3% | -2.3% | 7.2% | 16.6% | — |
| EPS Growth | -54.1% | -54.1% | 9.0% | 20.0% | — |
| Dividend Yield | 0.9% | 0.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
58.6%
EPS terminal req.
$0.24
Spread vs growth
-112.8%
5Y implied EPS CAGR
37.0%
EPS terminal req.
$0.29
Spread vs growth
-91.1%
10Y implied EPS CAGR
22.8%
EPS terminal req.
$0.47
Spread vs growth
-76.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-16.8%
Start / end P/E
25.1x → 45.0x
EPS bridge
0.13 → 0.06
Residual
-42.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.